```html

Gynecologic Cancer – A Comprehensive Medical Guide

Overview

Gynecologic cancers are malignancies that arise from a woman’s reproductive system. The term includes cancers of the:

• Uterus (endometrial cancer)
• Cervix (cervical cancer)
• Ovaries (ovarian cancer)
• Fallopian tubes (tubal cancer)
• Vulva and vagina (vulvar and vaginal cancers)

These cancers collectively account for about 13% of all cancers diagnosed in women worldwide and roughly 5–6% of cancer‑related deaths in women <sup>1</sup>. Incidence varies by region and by cancer type. For example, the United States sees about 63,000 new cases of gynecologic cancer each year, with ovarian cancer being the most lethal of the group despite its lower incidence compared with cervical cancer <sup>2</sup>.

Symptoms

Early-stage gynecologic cancers often produce vague or no symptoms, which is why routine screening (especially for cervical cancer) is critical. When symptoms do appear, they may include:

General symptoms

• Unexplained weight loss – loss of appetite or rapid weight decline.
• Fatigue – persistent tiredness not relieved by rest.
• Pelvic or abdominal pain – may be dull, cramping, or sharp.
• Bloating or increased abdominal girth – often described as "fullness."
• Changes in bowel or bladder habits – constipation, diarrhea, or urinary urgency/frequency.

Uterine (endometrial) cancer

• Abnormal uterine bleeding (post‑menopausal bleeding, heavy periods, or bleeding between periods).
• Spotting after intercourse.
• Pelvic pressure or a feeling of heaviness.

Cervical cancer

• Irregular vaginal bleeding (especially after sex or between periods).
• Unusual vaginal discharge (watery, bloody, or foul‑smelling).
• Pain during sexual intercourse (dyspareunia).
• Pelvic pain that worsens over time.

Ovarian and tubal cancer

• Abdominal bloating that does not go away.
• Early satiety – feeling full after a small amount of food.
• Persistent lower‑back or pelvic pain.
• Changes in menstrual patterns (in pre‑menopausal women).

Vulvar and vaginal cancers

• Visible sore, lump, or skin change on the vulva.
• Persistent itching, burning, or irritation.
• Bleeding or discharge that is not related to menstrual cycles.
• Pain during intercourse or while sitting.

Causes and Risk Factors

While the exact cause of most gynecologic cancers remains unknown, several well‑studied risk factors increase the likelihood of developing these malignancies.

Endometrial (uterine) cancer

• Prolonged estrogen exposure without progesterone (e.g., obesity, early menarche, late menopause).
• Polycystic ovary syndrome (PCOS).
• Family history of Lynch syndrome or hereditary nonpolyposis colorectal cancer (HNPCC).
• Diabetes and hypertension.

Cervical cancer

• Persistent infection with high‑risk human papillomavirus (HPV) types 16, 18, 31, 33, etc.
• Early onset of sexual activity and multiple sexual partners.
• Smoking and long‑term use of oral contraceptives (≥5 years).
• Immunosuppression (e.g., HIV, transplant medications).

Ovarian cancer

• Age – risk rises sharply after age 50.
• Family history of BRCA1/BRCA2 mutations or hereditary breast‑ovarian cancer syndrome.
• Never having been pregnant (nulliparity) or having infertility.
• Endometriosis (particularly for clear‑cell and endometrioid subtypes).

Vulvar and vaginal cancers

• HPV infection (especially for vulvar squamous cell carcinoma).
• Smoking.
• Lichen sclerosus or other chronic vulvar dermatoses.
• History of cervical or vaginal intraepithelial neoplasia.

Diagnosis

Accurate diagnosis requires a combination of clinical evaluation, imaging, and laboratory testing.

Medical history & physical exam

• Detailed symptom history and risk‑factor assessment.
• Pelvic examination, including visual inspection of the vulva, vagina, cervix, and bimanual exam to palpate the uterus and ovaries.

Screening & early detection tests

• Pap smear (Pap test) – detects precancerous cervical changes; recommended every 3 years for women 21–65.
• HPV DNA testing – primary screening or co‑testing with Pap for women ≥30 years.
• Transvaginal ultrasound – often used to evaluate ovarian masses.
• Endometrial biopsy – indicated for abnormal uterine bleeding in post‑menopausal women.

Diagnostic imaging

• Pelvic MRI – superior soft‑tissue resolution for local staging.
• CT scan – assesses distant spread (metastasis) to lungs, liver, or lymph nodes.
• PET‑CT – combined metabolic and anatomic imaging useful for staging, especially in ovarian cancer.

Pathology

• Biopsy (cervical cone, endometrial curettage, image‑guided needle biopsy of ovarian mass) provides tissue for histologic diagnosis.
• Immunohistochemistry and molecular testing (BRCA, mismatch repair proteins) guide treatment decisions.

Treatment Options

Treatment is individualized based on cancer type, stage, patient age, desire for fertility, and overall health.

Surgical Management

• Hysterectomy (total, radical) – removal of uterus, often with cervix and part of the vaginal cuff for endometrial or cervical cancer.
• Salpingo‑oophorectomy – removal of fallopian tubes and ovaries; performed with hysterectomy in many cases.
• Ovarian cancer debulking – optimal cytoreductive surgery aims to leave <1 cm of residual tumor.
• Vulvectomy or vaginectomy – for vulvar or vaginal cancers.
• Minimally invasive (laparoscopic/robotic) approaches are increasingly used for early‑stage disease.

Radiation Therapy

• External‑beam radiation (EBRT) – standard for many cervical and endometrial cancers.
• Brachytherapy – internal radiation that delivers high doses directly to the tumor while sparing surrounding tissue.
• Often combined with chemotherapy (chemoradiation) for locally advanced disease.

Chemotherapy

• Common regimens: carboplatin + paclitaxel (first‑line for ovarian and endometrial cancers).
• High‑dose cisplatin is a backbone of concurrent chemoradiation for cervical cancer.
• Targeted agents: bevacizumab (anti‑VEGF) for recurrent ovarian cancer; PARP inhibitors (olaparib, niraparib) for BRCA‑mutated tumors.

Immunotherapy

• PD‑1 inhibitors (e.g., pembrolizumab) approved for MSI‑high or mismatch repair‑deficient endometrial cancers.
• Research ongoing for checkpoint inhibitors in ovarian and cervical cancers.

Hormonal & Targeted Therapies

• Progestins (medroxyprogesterone acetate) for selected low‑grade endometrial cancers.
• Hormone therapy (tamoxifen, aromatase inhibitors) sometimes used in recurrent ovarian cancer expressing hormone receptors.

Lifestyle & Supportive Measures

• Nutrition counseling to maintain weight and support healing.
• Physical therapy to improve mobility after pelvic surgery.
• Psychosocial support, fertility counseling, and survivorship programs.

Living with Gynecologic Cancer

Managing life after diagnosis involves both medical follow‑up and day‑to‑day strategies.

Follow‑up care

• Regular pelvic exams and imaging as recommended by your oncologist (typically every 3–6 months for the first two years).
• Monitoring tumor markers when appropriate (e.g., CA‑125 for ovarian cancer).
• Vaccinations – keep flu and COVID‑19 vaccines up to date; consider HPV vaccine if not previously immunized.

Physical health

• Gentle exercise (walking, yoga, swimming) improves fatigue and mood.
• Balanced diet high in fruits, vegetables, whole grains, and lean protein.
• Manage lymphedema (especially after lymph node removal) with compression garments and specialist therapy.

Emotional well‑being

• Join support groups (online or in‑person) for women with similar diagnoses.
• Consider counseling or cognitive‑behavioral therapy for anxiety or depression.
• Mind‑body practices—meditation, deep‑breathing, guided imagery—can reduce stress.

Fertility & Sexual Health

• If fertility preservation is a goal, discuss egg or embryo freezing before treatment.
• Post‑treatment vaginal moisturizers and lubricants can alleviate dryness.
• Pelvic floor physical therapy helps address dyspareunia or urinary symptoms.

Prevention

Many gynecologic cancers are preventable or can be detected early.

• HPV vaccination – three‑dose series (Gardasil 9) protects against >90% of cervical, vulvar, and vaginal cancers. Recommended for ages 9–26, and up to age 45 after shared decision‑making.
• Routine cervical screening (Pap + HPV testing) – reduces cervical cancer mortality by >70% (CDC).
• Maintain a healthy weight; obesity is a major risk for endometrial and ovarian cancers.
• Limit tobacco use – smoking increases risk for cervical and vulvar cancers.
• Use barrier contraception and limit the number of sexual partners to reduce HPV exposure.
• Consider prophylactic surgery (e.g., risk‑reducing salpingo‑oophorectomy) for women with confirmed BRCA mutations after childbearing is complete.

Complications

If left untreated or if treatment complications arise, patients may experience:

• Metastasis – spread to lungs, liver, brain, or distant lymph nodes.
• Severe anemia or bleeding from tumor invasion of uterine or cervical vessels.
• Obstruction of the bowel or urinary tract leading to hydronephrosis or bowel perforation.
• Chronic pelvic pain and neuropathic pain from nerve involvement.
• Lymphedema after extensive lymph node dissection.
• Fertility loss and hormonal deficiencies (e.g., premature menopause after oophorectomy).
• Psychological distress, depression, and anxiety.

When to Seek Emergency Care

---

References:

1. World Health Organization. Cancer Fact Sheets: Cervical Cancer. 2023.
2. American Cancer Society. Gynecologic Cancers Statistics. 2024.
3. Centers for Disease Control and Prevention. HPV Vaccine Recommendations. Updated 2024.
4. Mayo Clinic. Endometrial cancer: Symptoms & causes. 2024.
5. Cleveland Clinic. Ovarian Cancer Treatment Options. 2023.
6. National Institutes of Health. PARP Inhibitors in BRCA‑mutated Ovarian Cancer. 2022.

```